At the American Society of Hematology Annual Meeting last December, bluebird and Celgene provided an extremely encouraging clinical update on bb2121's ongoing dose-escalation study. The two companies ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback